Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation

Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation

Abstract Background A recent in vitro pilot investigation reported Rituximab significantly reduced natural killer (NK) cell cytotoxicity in healthy donors. Chronic fatigue syndrome/Myalgic encephalomyelitis (CFS/ME) is a debilitating disorder of unknown etiology. A consistent finding is a significan...

Full description

Bibliographic Details
Main Authors: Natalie Eaton, Hélène Cabanas, Cassandra Balinas, Anne Klein, Donald Staines, Sonya Marshall-Gradisnik
Format: Article
Language:English
Published: BMC 2018-03-01
Series:BMC Pharmacology and Toxicology
Subjects:
Chronic fatigue syndrome
Myalgic encephalomyelitis
Rituximab
Natural killer cells
Lytic proteins
Degranulation
Online Access:http://link.springer.com/article/10.1186/s40360-018-0203-8

Internet

http://link.springer.com/article/10.1186/s40360-018-0203-8

Similar Items